Celestica's Post-Earnings Drop Reinforces Execution Risk Narrative

What happened

Celestica reported strong Q1 results with revenue up 53% YoY and raised FY2026 guidance, yet shares fell 14%, reflecting market skepticism about sustainability. The CCS segment, which drives 80% of revenue, grew 76% YoY and maintained a healthy 8.6% margin, but the company is executing a massive ~$1B capex ramp in 2026. Customer concentration remains extreme (35% from one customer), and non-demand bottlenecks like power/grid constraints could disrupt deployments. The DeepValue report rates CLS a WAIT at $361.50, with a $300 attractive entry and $420 trim level, noting that the elevated valuation (43x P/E) leaves no margin of safety. Until the next two quarters confirm stable CCS margins and working capital normalization, the risk of a utilization-driven air pocket outweighs the potential upside.

Implication

The post-earnings selloff despite strong results illustrates that the market is already discounting the possibility of execution missteps, validating the WAIT rating. Key near-term monitorables include the pace of capex spending, any disclosure of program delays tied to power/grid constraints, and CCS margin stability above 8.5%. A/R sales (sold $314M in Q1) need to decline to support the free cash flow narrative; if they remain elevated, cash conversion concerns will intensify. In the bull case, hyperscaler capex continues to grow, but the stock's current valuation (P/E 43) already prices in that favorable scenario, offering limited upside. The attractive entry point of $300 provides a 20%+ margin of safety to the base case value of $390, and investors should wait for that level or confirmation of clean execution.

Thesis delta

The fundamental thesis remains unchanged: CLS's strong AI demand backdrop is offset by execution risk from a large capex ramp and customer concentration. The market's negative reaction to a beat-and-raise underscores that the stock is already pricing in sustained success, leaving no room for missteps. The near-term risk/reward remains unfavorable until the next two quarters provide evidence that the capacity ramp is on track and not constrained by non-demand bottlenecks.